Postdiagnosis antidepressant use reduced mortality risk among patients with hepatocellular carcinoma, according to data published in JAMA Network Open.
The inverse relationship between postdiagnosis antidepressant use and decreased mortality risk remained consistent across antidepressant classes, researchers noted.
“Notably, we observed a consistent inverse association between postdiagnosis antidepressant use and mortality risk across various comorbidity subgroups, encompassing [hepatitis B virus] infection, [hepatitis C virus] infection, liver cirrhosis and alcohol use disorder,”